# Nuclide record radium-223 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/radium-223/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "radium-223" ;
  schema:name "Radium-223 dichloride"@en ;
  schema:description "Radium-223 was the first alpha-emitting drug ever approved (2013). It homes to bone like calcium and treats prostate cancer that has spread only to bone."@en ;
  schema:url <https://nuclide.cc/drugs/radium-223/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Radium-223> ;
  owl:sameAs <http://www.wikidata.org/entity/Q18888805> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radium-223%20dichloride> ;
  nuclide:status "approved" ;
  nuclide:modality "Targeted alpha therapy (bone-seeking)" ;
  schema:alternateName "Xofigo" ;
  nuclide:approval "US 2013: Symptomatic bone-metastatic CRPC without visceral disease" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ra-223/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:companies <https://nuclide.cc/companies/bayer/> ;
  nuclide:terms <https://nuclide.cc/terms/alpha-vs-beta/> ;
  nuclide:trials <https://nuclide.cc/trials/alsympca/> .